Letrozole as Maintenance Therapy for Post-surgical Endometrial Cancer Patients With NSMP (NCT05454358) | Clinical Trial Compass
TerminatedPhase 2/3
Letrozole as Maintenance Therapy for Post-surgical Endometrial Cancer Patients With NSMP
Stopped: No enough participants
China12 participantsStarted 2022-08-02
Plain-language summary
Aim to investigate the effect of Letrozole as maintenance after adjuvant treatment on the prognosis of post-operative endometrial cancer patients with non-specific molecular profile.
Who can participate
Age range18 Years – 80 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Older than 18 years old;
✓. Initial diagnosed with stage I-IV(FIGO2009) endometrial epithelial cancer, regardless of pathological types;
✓. Surgery must have included a hysterectomy, bilateral salpingo-oophorectomy and sentinel node biopsy; pelvic lymph node sampling and para-aortic lymph node sampling are optional;
✓. Life expectancy of 2 or more years.
✓. Confirmed NSMP with intermediate or higher prognostic risk according to post-operative clinical pathological assessment and molecular classification;
✓. Intermediate prognostic risk group:
✓. High-intermediate prognostic risk group:
✓. High prognostic risk group:
Exclusion criteria
✕. Endometrial stromal tumor;
✕. Recurrent endometrial cancers;
✕. Patients with low prognostic risk according to post-operative clinical pathological assessment ( Stage IA endometrioid + low-grade\* +LVSI negative or focal);
✕. Patients require no adjuvant therapy after surgery;
✕. Negative expression in estrogen receptor or progesterone receptor according to post-operative Immunohistochemistry;
✕. Received other adjuvant therapy within 6 months before surgery: including neoadjuvant therapy, hormone therapy, targeted therapy, immunotherapy and biotherapy, etc;
✕. Patients with contraindications for letrozole;